These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4318029)

  • 41. [Effect of Bordetella pertussis on the lymphoid tissue o mice. 3. Effect on the kinetics of formation of antibodies against sheep erythrocytes by Bordetella pertussis].
    Finger H; Emmerling P; Tusch H; Bredt W
    Z Immunitatsforsch Allerg Klin Immunol; 1968; 136(3):268-84. PubMed ID: 4235333
    [No Abstract]   [Full Text] [Related]  

  • 42. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.
    Geurtsen J; Banus HA; Gremmer ER; Ferguson H; de la Fonteyne-Blankestijn LJ; Vermeulen JP; Dormans JA; Tommassen J; van der Ley P; Mooi FR; Vandebriel RJ
    Clin Vaccine Immunol; 2007 Jul; 14(7):821-9. PubMed ID: 17494641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant effect of Bordetella pertussis vaccine to sheep erythrocytes: enhancement of antibody formation by using subcutaneous administration of adjuvant and antigen.
    Murgo AJ; Athanassiades TJ
    Infect Immun; 1975 Nov; 12(5):969-77. PubMed ID: 1104487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stimulation of humoral antibody formation by polyanions. V. Relationship between enhancement of sheep red blood cell uptake by the spleen and adjuvant action of dextran sulfate.
    Diamantstein T; Meinhold H; Wagner B
    Eur J Immunol; 1971 Dec; 1(6):429-32. PubMed ID: 4947880
    [No Abstract]   [Full Text] [Related]  

  • 45. Preferential enhancement of IgE antibody formation by Bordetella pertussis.
    Suko M; Ogita T; Okudaira H; Horiuchi Y
    Int Arch Allergy Appl Immunol; 1977; 54(4):329-37. PubMed ID: 194843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant effects on poly I poly C in New Zealand mice.
    Jacobs ME; Steinberg AD; Gordon JK; Talal N
    Arthritis Rheum; 1972; 15(2):201-7. PubMed ID: 4554893
    [No Abstract]   [Full Text] [Related]  

  • 47. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
    Macdonald-Fyall J; Xing D; Corbel M; Baillie S; Parton R; Coote J
    Vaccine; 2004 Oct; 22(31-32):4270-81. PubMed ID: 15474718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunologic and biochemical properties of the histamine-sensitizing factor from Bordetella pertussis.
    Lehrer SB; Vaughan JH; Tan EM
    J Immunol; 1975 Jan; 114(1 Pt 1):34-9. PubMed ID: 46244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Possible mechanism of adjuvant action.
    Finger H
    Int Arch Allergy Appl Immunol; 1969; 36():Suppl:293-309. PubMed ID: 4313664
    [No Abstract]   [Full Text] [Related]  

  • 50. Do we need a new vaccine to control the re-emergence of pertussis?
    Mills KH; Ross PJ; Allen AC; Wilk MM
    Trends Microbiol; 2014 Feb; 22(2):49-52. PubMed ID: 24485284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A.
    Agnolon V; Bruno C; Leuzzi R; Galletti B; D'Oro U; Pizza M; Seubert A; O'Hagan DT; Baudner BC
    Int J Pharm; 2015 Aug; 492(1-2):169-76. PubMed ID: 26149936
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantity of antibody synthesized in a single cell during the primary immune response.
    Henss J; Bodemer W; Batsford SR; Vogt A
    Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):381-7. PubMed ID: 190809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic control of immune responsiveness to a glutamic acid, alanine, tyrosine copolymer in mice. I. Linkage of responsiveness to H-2 genotype.
    Martin WJ; Maurer PH; Benacerraf B
    J Immunol; 1971 Sep; 107(3):715-8. PubMed ID: 4328471
    [No Abstract]   [Full Text] [Related]  

  • 55. The influence of adjuvants on the generation of autoantibody and specific suppression in rat erythrocyte-immunized mice.
    Elliott JI; Hutchings P; Malkovsky M; Cooke A
    Scand J Immunol; 1992 May; 35(5):501-9. PubMed ID: 1579855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvants and in vitro antibody production.
    Maillard JL; Bloom BR
    Adv Exp Med Biol; 1973; 29(0):567-71. PubMed ID: 4211780
    [No Abstract]   [Full Text] [Related]  

  • 57. Vitamin A: adjuvant and steroid antagonist in the immune response.
    Cohen BE; Cohen IK
    J Immunol; 1973 Nov; 111(5):1376-80. PubMed ID: 4583075
    [No Abstract]   [Full Text] [Related]  

  • 58. [Hypersplenism in the mouse following injection of Bordetella pertussis].
    Finger H; Beneke G; Emmerling P
    Z Naturforsch B; 1968 Feb; 23(2):288-9. PubMed ID: 4385992
    [No Abstract]   [Full Text] [Related]  

  • 59. The influence of Bordetella pertussis on the kinetics of antibody production to sheep red blood cells in NMRI mice.
    Finger H; Emmerling P
    Experientia; 1968 Aug; 24(8):832-3. PubMed ID: 4300810
    [No Abstract]   [Full Text] [Related]  

  • 60. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice.
    Orr B; Douce G; Baillie S; Parton R; Coote J
    Vaccine; 2007 Jan; 25(1):64-71. PubMed ID: 16916566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.